SCHEMBL20382002

SCHEMBL20382002

CC(C)(C)OC(=O)N[C@H]1CC2CC[C@H](C1)N2c1ccc(B2OC(C)(C)C(C)(C)O2)cn1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.53
RET P07949 1/20 0.46
DGAT1 O75907 1/20 0.42
AAK1 Q2M2I8 2/20 0.41
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
JAK1 P23458 5/20 0.40
JAK2 O60674 2/20 0.40
HSP90AA1 P07900 3/20 0.39
HSP90AB1 P08238 3/20 0.39
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
PIK3R1 P27986 1/20 0.36
PIK3CA P42336 1/20 0.36
JAK3 P52333 1/20 0.36
BTK Q06187 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22642376 1.00 USP30 (0.53) USP30RETDGAT1AAK1KMT2A
SCHEMBL20962669 1.00 USP30 (0.53) USP30RETDGAT1AAK1KMT2A
SCHEMBL29516606 1.00 USP30 (0.53) USP30RETDGAT1AAK1KMT2A
SCHEMBL18389879 1.00 USP30 (0.53) USP30RETDGAT1AAK1KMT2A
SCHEMBL18390070 1.00 USP30 (0.53) USP30RETDGAT1AAK1KMT2A
SCHEMBL18713242 1.00 USP30 (0.53) USP30RETDGAT1AAK1KMT2A
SCHEMBL18713031 1.00 USP30 (0.53) USP30RETDGAT1AAK1KMT2A
SCHEMBL20965484 0.96 USP30 (0.51) USP30RETDGAT1AAK1KMT2A
SCHEMBL20349483 0.96 USP30 (0.51) USP30RETDGAT1AAK1KMT2A
SCHEMBL20946119 0.87 USP30 (0.44) USP30DGAT1HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190127375-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2019-05-02 US disclosed
US-10023570-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127375-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP30 3892/4885RET 1/4885DGAT1 4847/4885
US-10023570-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF USP30 3892/4885RET 1/4885DGAT1 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.